By Mariam Sunny and Kamal Choudhury (Reuters) -The U.S. Food and Drug Administration has approved a prefilled syringe version ...

Prefilled syringes (PFSs) have gained market share ... levels of uptake currently seen in Western Europe. In influenza vaccination, PFSs may cost more per dose than multidose vials (MDVs), but ...

Already thriving with a successful launch of infused Vyvgart and its subcutaneous follow-on Vyvgart Hytrulo to the tune of $2 ...

Vimkunya is now available in the US for the prevention of disease caused by chikungunya virus in individuals 12 years of age ...

Argenx’s VYVGART Hytrulo prefilled syringe for self-injection has received FDA approval for the treatment of adult patients ...

US mRNA specialist Moderna has announced that the German Standing Committee on Vaccination (STIKO) has issued a ...

VIMKUNYA was approved by the U.S. Food and Drug Administration (FDA) and the European Commission in February 2025 6,7. Bavarian Nordic has also filed for approval of the vaccine in the United Kingdom ...

mResvia’s prescribing information indicates that the vaccine was 78.7% effective ... up against the convenience of mResvia’s prefilled syringe formulation and no reported cases of Guillain ...

The global market for prefilled syringes is expanding, driven by the rising prevalence of chronic illnesses, greater use of biologics and biosimilars, and a growing trend toward self-injection.

US FDA approves syringe version of Argenx's immune disorder drug The U.S. Food and Drug Administration has approved a prefilled syringe ... COVID shot's efficacy Vaccine maker Novavax's shares ...

2010 Expert Reviews Ltd. Cite this: Vaccine Presentation in the USA: Economics of Prefilled Syringes versus Multidose Vials for Influenza Vaccination - Medscape - Nov 01, 2010.